New Hampshire 2024 Regular Session

New Hampshire Senate Bill SB560

Introduced
12/14/23  
Refer
12/14/23  
Report Pass
2/22/24  
Engrossed
3/12/24  
Refer
3/12/24  
Report Pass
5/1/24  
Enrolled
6/19/24  
Chaptered
7/10/24  

Caption

Relative to establishing a committee to study the impact of pharmacy benefit manager operations on cost, administration, and distribution of prescription drugs.

Impact

By forming this committee, SB560 seeks to enhance understanding of how PBM practices affect healthcare costs and the accessibility of medications. Specifically, the committee will evaluate claims from PBMs regarding cost savings, the use of clawbacks, and the implications of PBMs steering consumers towards specific pharmacies. These evaluations will involve gathering data on the effects of PBMs on health insurers' overall expenses and assess how plan designs impact consumer prices.

Summary

Senate Bill 560 establishes a committee tasked with studying the impact of pharmacy benefit manager (PBM) operations on the cost, administration, and distribution of prescription drugs in New Hampshire. The bill aims to address concerns surrounding the influence PBMs have on drug pricing and access, which have been increasingly scrutinized in the context of rising healthcare costs. The committee is mandated to investigate various aspects of PBM operations and their relationship with insurers, pharmacies, and consumers, looking to provide insights that could inform future legislative actions.

Contention

The bill is significant as it highlights a growing concern over the role of PBMs within the pharmaceutical supply chain. Advocates for the bill argue that comprehensive oversight and transparency in PBM operations are crucial for reducing costs for consumers and improving their access to medications. However, there may be opposition from PBMs and other stakeholders who could be concerned that increased scrutiny might lead to regulatory burdens or threaten their business models. The outcomes of the committee's study could influence future legislative actions related to pharmacy benefit managers.

Companion Bills

No companion bills found.

Previously Filed As

NH SSB1207

A bill for an act relating to pharmacy benefits managers, pharmacies, and prescription drugs.

NH HR948

House Study Committee on Pharmacy Benefits Managers and Consumer Access to Prescription Medications; create

NH SR927

Senate Pharmacy Benefits Managers and Consumer Access to Prescription Medications Study Committee; create

NH SSB1074

A bill for an act relating to pharmacy benefits managers, pharmacies, and prescription drugs and including applicability provisions.(See SF 383.)

NH HSB99

A bill for an act relating to pharmacy benefits managers, pharmacies, and prescription drugs and including applicability provisions.(See HF 852.)

NH HF852

A bill for an act relating to pharmacy benefits managers, pharmacies, and prescription drugs and including applicability provisions.(Formerly HSB 99.)

NH SB478

relative to strengthening prescription drug affordability and pharmacy benefits manager accountability.

NH SB665

(New Title) relative to pharmacy benefits managers, managed care laws, notice of drug pricing options and pharmacy benefit manager business practices.

NH HF213

A bill for an act relating to pharmacy benefits managers, pharmacies, and prescription drug benefits, and including applicability provisions.

NH HB1268

(Second New Title) modifying the structure and administration of home education programs and relative to pharmacy benefits managers, managed care laws, notice of drug pricing options and pharmacy benefit manager business practices.

Similar Bills

US HR198

Providing for the expenses of certain committees of the House of Representatives in the One Hundred Nineteenth Congress.

MN HC1

A house concurrent resolution relating to the regent nomination joint committee.

IL HR0020

HOUSE RULES-AMEND

CA AB1350

Employment Development Department: policies and practices.

NM HJM2

Combine Standing & Interim Committees

MN HC2

A House concurrent resolution relating to the adjournment of the House of Representatives and Senate until 2026.

CA SB829

California Institute for Scientific Research: CalRx Initiative: vaccines.

AR HB1573

To Reorganize The Standing Committees And The Subject Matter Interim Committees Of The House Of Representatives.